• Product nameAnti-LRIG1 antibody
    See all LRIG1 primary antibodies
  • Description
    Rabbit polyclonal to LRIG1
  • Tested applicationsSuitable for: WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide (human) conjugated to KLH. The peptide corresponded to part of the cytoplasmic tail (C-terminal), sequence is proprietary.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: None
    Constituents: PBS, pH 7.4
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products


Our Abpromise guarantee covers the use of ab36707 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 155 kDa (predicted molecular weight: 143 kDa).Can be blocked with LRIG1 peptide (ab207566).
IHC-P Use at an assay dependent concentration.


  • FunctionAct as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
  • Tissue specificityWidely expressed.
  • Sequence similaritiesContains 3 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 15 LRR (leucine-rich) repeats.
    Contains 1 LRRCT domain.
    Contains 1 LRRNT domain.
  • DomainThe LRRs and the Ig-domains are each sufficient for EGFR/ERBB1 binding. This interaction is abolished only when these two domains are deleted.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Leucine rich repeat protein antibody
    • Leucine rich repeat protein LRIG1 antibody
    • leucine rich repeats and immunoglobulin like domains 1 antibody
    • Leucine-rich repeats and immunoglobulin-like domains protein 1 antibody
    • leucine-rich repeats- and immunoglobulin-like domains-cotnaining protein 1 antibody
    • LIG 1 antibody
    • LIG-1 antibody
    • LIG1 antibody
    • Lrig1 antibody
    • LRIG1_HUMAN antibody
    • Ortholog of mouse integral membrane glycoprotein LIG 1 antibody
    see all

Anti-LRIG1 antibody images

  • ab36707 at 1/200 staining human anal cancer tissue sections by IHC-P. The tissue was formaldehyde fixed and a heat mediated antigen retrieval step was performed in citrate buffer. The tissue was blocked with serum and then incubated with the antibody for 45 minutes at 22°C. An HRP conjugated goat anti-rabbit antibody was used as the secondary.

    See Abreview

  • ab36707 staining LRIG1 in Mouse brain tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde and blocked with 10% serum for 1 hour at 20°C. No antigen retrieval was performed. Samples were incubated with primary antibody (1/400 in PBS) for 12 hours at 4°C. A Biotin-conjugated Goat anti-rabbit polyclonal (1/200) was used as the secondary antibody.

    See Abreview

  • Anti-LRIG1 antibody (ab36707) at 1 µg/ml + Human colon tissue lysate - total protein (ab30051) at 10 µg

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 143 kDa
    Observed band size : 155 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 37 kDa. We are unsure as to the identity of these extra bands.

    Exposure time : 12 minutes

References for Anti-LRIG1 antibody (ab36707)

This product has been referenced in:

See 1 Publication for this product

Product Wall

Thank you very much for your call today and for letting us know about the trouble with ab36707.

Your credit note ID is ***.

I am sorry that this antibody did not perform as stated on the datasheet. If payment has already been made ...

Read More

Thank you for contacting us. I can confirm the following information:

- The antibody is affinity purified against the immunizing peptide, therefore all antibodies present will bind this sequence.
- The LRIG1 peptide used to generate thi...

Read More

Thank you for your call on Friday and for your interest in ab36707.

As we discussed, we fully guarantee this antibody to work in Western blot and IHC-P with mouse samples. Should you have any trouble using ab36707 in these applications, pleas...

Read More

Thank you for you reply.

Your credit note IDs are ***** & *********.

I am sorry that these antibodies did not perform as stated on the datasheet, I have asked our Finance department to issue a credit note for you for all of the...

Read More

Thank you for contacting Abcam.

I am sorry about all of the problems you have been having with these antibodies.

It would greatly be appreciated if you could send me some of the images that you are getting using these antibodies and...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (Brain)
Specification Brain
Fixative Paraformaldehyde
Antigen retrieval step None
Permeabilization No
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Sep 14 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (anal cancer)
Specification anal cancer
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate Buffer pH 6.0
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 22°C

Abcam user community

Verified customer

Submitted Nov 02 2007